News

Arsanis and X4 Pharmaceuticals Agree to Merger

ERC consolidator grant for Kikuë Tachibana

Study on parasites in dog faeces comes to surprising conclusion

Brigitte Ederer joins the Supervisory Board of Marinomed

EUR 96 million of EIF and aws finance for innovative businesses in Austria

EMERGENT BIOSOLUTIONS AND VALNEVA REPORT POSITIVE PHASE 1 RESULTS FOR THEIR VACCINE CANDIDATE AGAINST THE ZIKA VIRUS

Rentschler Fill Solutions inaugurates state-of-the-art fill and finish facility

Marinomed launches Initial Public Offering on the Vienna Stock Exchange

HOOKIPA Appoints Julie O’Neill as a Non-Executive Director

Arsanis Reports Financial Results for Third Quarter 2018

Themis Bioscience Postpones its Listing on Euronext Amsterdam

Valneva Reports Nine Month Results for 2018, Confirms Guidance, Strengthens Balance Sheet with €50m Financing

Themis Bioscience Publishes Compelling Phase 2 Results for Lead Vaccine Candidate against Chikungunya Fever in the Lancet

EANS-News: Marinomed Biotech AG / Marinomed announces its intention to launch an Initial Public Offering and listing on the Vienna Stock Exchange

ACIB: Targeting cancer

Lexogen supports thousands of RNA researchers worldwide by partnering with the RNA Society in their 2018/19 RNA Salon initiative

Valneva Receives Positive Feedback from EMA on its further Development for Lyme Disease Vaccine VLA15

Valneva Announces Progress of Chikungunya Vaccine

Themis Bioscience Announces Exclusive Licensing Agreement with Max- Planck-Innovation to Develop and Commercialize Oncolytic Virotherapies Themis to expand measles vector immunomodulation portfolio into oncology indications

Nanocages in the lab and in the computer: how DNA-based dendrimers transport nanoparticles